What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 5 minute read Pharma Industry News Why amylin is gaining pharma attention in obesity drug development: From amycretin to AZD6234 Discover how Novo Nordisk, AstraZeneca, and others are betting on amylin-based obesity drugs like amycretin and AZD6234 to reshape metabolic care. byPallavi MadhirajuJuly 4, 2025